| Recruiting | A Study of HRS-2129 in Patients With Diabetic Peripheral Neuropathic Pain NCT07377721 | Shandong Suncadia Medicine Co., Ltd. | Phase 1 |
| Recruiting | A Chronic Pain Master Protocol (CPMP): A Study of LY4065967 in Participants With Diabetic Peripheral Neuropath NCT07285018 | Eli Lilly and Company | Phase 2 |
| Recruiting | Evaluation of Efficacy and Safety of Suzetrigine (SUZ) for Pain Associated With Diabetic Peripheral Neuropathy NCT07231419 | Vertex Pharmaceuticals Incorporated | Phase 3 |
| Not Yet Recruiting | Evaluate the Efficacy and Safety of HL-1186 in Patients With Diabetic Peripheral Neuropathic Pain NCT07159243 | Shanghai Yidian Pharmaceutical Technology Development Co., Ltd. | Phase 2 |
| Active Not Recruiting | A Study to Evaluate the Safety and Effectiveness of Mirogabalin in Chinese Adult Patients With Diabetic Periph NCT06812117 | Daiichi Sankyo | — |
| Completed | Buerger Exercises With Whole Body Vibration in Diabetic Peripheral Neuropathy NCT06737861 | Riphah International University | N/A |
| Active Not Recruiting | Evaluation of the Long-term Safety and Effectiveness of Suzetrigine (SUZ) in Participants With Painful Diabeti NCT06696443 | Vertex Pharmaceuticals Incorporated | Phase 3 |
| Recruiting | A Study of Medical Cannabis Aerosol Via the Fixed-dose Syqe Inhaler as an Add-on Treatment of Diabetic Periphe NCT06490445 | Syqe Medical | Phase 2 |
| Recruiting | Evaluation of Efficacy and Safety of VX-993 for Pain Associated With Diabetic Peripheral Neuropathy NCT06619860 | Vertex Pharmaceuticals Incorporated | Phase 2 |
| Recruiting | Evaluation of Efficacy and Safety of Suzetrigine for Pain Associated With Diabetic Peripheral Neuropathy NCT06628908 | Vertex Pharmaceuticals Incorporated | Phase 3 |
| Completed | Real-World Pharmacological Treatment Pattern of Neuropathic Pain in China NCT06546202 | Daiichi Sankyo | — |
| Recruiting | MAD Study to Assess the Safety, Tolerability, PKs and Efficacy of YJ001 for Spray Use in Patients With DPNP NCT06361108 | Zhejiang Hanmai Pharmaceutical Technology Co., Ltd. | Phase 1 |
| Recruiting | Efficacy and Safety of HSK16149 Capsule in Chinese Patients With Diabetic Peripheral Neuropathic Pain Who Had NCT06490484 | Haisco Pharmaceutical Group Co., Ltd. | Phase 2 |
| Recruiting | Evaluate the Efficacy and Safety of JMKX000623 in Participants With Diabetic Peripheral Neuropathic Pain NCT06221241 | Jemincare | Phase 2 |
| Completed | A Dose-ranging Study in Patients With Diabetic Peripheral Neuropathic Pain (DPNP) NCT06203002 | Lexicon Pharmaceuticals | Phase 2 |
| Unknown | Effectiveness of Electroacupuncture in the Treatment of Diabetic Peripheral Neuropathy NCT06054087 | Zhejiang Chinese Medical University | N/A |
| Terminated | A Study of RTA 901 (BIIB143) in Participants With Diabetic Peripheral Neuropathic Pain NCT05895552 | Reata, a wholly owned subsidiary of Biogen | Phase 2 |
| Unknown | Diabetic Neuropathic Pain Relief, 6 Weeks Dosage Sublingual Water-soluble CBD/PEA NCT05766969 | Pure Green Pharmaceuticals Inc. | Phase 1 / Phase 2 |
| Unknown | To Evaluate the Efficacy and Safety of HSK16149 With L-carnitine in Diabetic Peripheral Neuralgia Patients in NCT06122012 | Haisco Pharmaceutical Group Co., Ltd. | N/A |
| Completed | A Chronic Pain Master Protocol (CPMP): A Study of LY3857210 in Participants With Diabetic Peripheral Neuropath NCT05620576 | Eli Lilly and Company | Phase 2 |
| Unknown | Efficacy of Pregabalin Vs Duloxetine in Diabetic Peripheral Neuropathic Pain at Variable Dose NCT05292066 | Aga Khan University | EARLY_Phase 1 |
| Withdrawn | Exercise Induced Hypoalgesia Diabetes NCT05296642 | University of Miami | N/A |
| Completed | Slider Versus Tensioner Neural Mobilization in Diabetic Peripheral Neuropathy NCT05349357 | Riphah International University | N/A |
| Completed | Chronic Pain Master Protocol (CPMP): A Study of LY3526318 in Participants With Diabetic Peripheral Neuropathic NCT05177094 | Eli Lilly and Company | Phase 2 |
| Recruiting | Effect of Electroacupuncture on Sensitive Symptoms of Distal Diabetic Peripheral Neuropathy NCT05521737 | Instituto Mexicano del Seguro Social | N/A |
| Unknown | The Effect of YJ001 on Diabetic Peripheral Neuropathic Pain. NCT04953221 | Peking University Third Hospital | — |
| Terminated | Chronic Pain Master Protocol (CPMP): A Study of LY3556050 in Participants With Diabetic Peripheral Neuropathic NCT04707157 | Eli Lilly and Company | Phase 2 |
| Unknown | rTMS on Diabetic Peripheral Neuropathic Pain NCT04833660 | Min Cheol Chang | N/A |
| Unknown | Using Cannabidiol to Treat Diabetic Peripheral Neuropathy of the Feet NCT04679545 | Pure Green | Phase 2 |
| Unknown | To Evaluate the Efficacy and Safety of HSK16149 Capsule in Chinese Patients With Diabetic Peripheral Neuropath NCT04647773 | Haisco Pharmaceutical Group Co., Ltd. | Phase 2 / Phase 3 |
| Completed | Efficacy and Safety of ETX-018810 for the Treatment of Diabetic Peripheral Neuropathic Pain NCT04688671 | Eliem Therapeutics (UK) Ltd. | Phase 2 |
| Completed | Chronic Pain Master Protocol (CPMP): A Study of LY3016859 in Participants With Diabetic Peripheral Neuropathic NCT04476108 | Eli Lilly and Company | Phase 2 |
| Completed | Efficacy and Safety of NYX-2925 in Subjects With Neuropathic Pain Associated With Diabetic Peripheral Neuropat NCT04146896 | Aptinyx | Phase 2 |
| Completed | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled 14-week Study of DS-5565 in Chinese Patien NCT04094662 | Daiichi Sankyo Co., Ltd. | Phase 3 |
| Completed | Neuropathic Pain in Elderly People With Diabetes: Impact on Quality of Life and Cognition NCT03909841 | Queen Elizabeth Hospital, Hong Kong | — |
| Completed | DS-5565 Phase III Study for Renal Impairment in Japanese Subjects NCT02607280 | Daiichi Sankyo Co., Ltd. | Phase 3 |
| Completed | Effect of NRD135S.E1 in Peripheral Neuropathic Pain in Diabetic Patients NCT02345291 | Novaremed Ltd. | Phase 2 |
| Completed | A Study of Duloxetine (LY248686) in Participants With Diabetic Peripheral Neuropathic Pain (DPNP) NCT02417935 | Eli Lilly and Company | Phase 4 |
| Completed | DS-5565 Phase III Study for Diabetic Peripheral Neuropathic Pain NCT02318706 | Daiichi Sankyo Co., Ltd. | Phase 3 |
| Terminated | Ranolazine for Diabetic Peripheral Neuropathic Pain (DPNP) NCT02156336 | Horizons International Peripheral Group | Phase 4 |
| Completed | Efficacy & Safety Study of Nonracemic Methadone for the Relief of Chronic Peripheral Neuropathic Pain NCT01429181 | MetaPharm, Inc. | Phase 2 |
| Completed | Efficacy and Safety of Gabapentin/B-complex Versus Pregabalin in Diabetic Peripheral Neuropathy Pain Managemen NCT01364298 | Merck KGaA, Darmstadt, Germany | Phase 4 |
| Completed | Diabetic Peripheral Neuropathic Pain (DPNP) NCT01314222 | Bristol-Myers Squibb | Phase 2 |
| Completed | Cognitive Behavioral Therapy for Diabetic Neuropathic Pain NCT00829387 | VA Connecticut Healthcare System | N/A |
| Completed | Study of the Safety and Efficacy of RGH-896 in Patients With Diabetic Peripheral Neuropathic Pain NCT00838799 | Forest Laboratories | Phase 2 |
| Completed | Study of the Safety, Tolerability and Efficacy of V3381 in Patients With Diabetic Peripheral Neuropathic Pain NCT00794430 | Vernalis (R&D) Ltd | Phase 2 |
| Approved For Marketing | Duloxetine Compassionate Use in Patients Who Have Completed a Previous Neuroscience Duloxetine Clinical Trial NCT00071708 | Eli Lilly and Company | — |